Galectin <a href="https://laohu8.com/S/LENZ">Therapeutics</a> reports Q3 2025 financial results and updates on belapectin trial data
Galectin Therapeutics Inc. reported a net loss applicable to common stockholders of $8.2 million, or ($0.13) per share, for the quarter ended September 30, 2025, compared to a net loss of $11.2 million, or ($0.18) per share, for the same period in 2024. Research and development expenses were $2.6 million, down from $7.6 million in the prior year, primarily due to the conclusion of expenditures related to the NAVIGATE clinical trial. General and administrative expenses were $1.6 million, compared to $1.5 million in the previous year. As of September 30, 2025, the company held $11.5 million in cash and cash equivalents and entered into a $10 million line of credit in July 2025. The company submitted the NAVIGATE data package to the FDA and expects guidance by year-end, with sufficient cash to fund current plans through June 30, 2026.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Galectin Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001140361-25-042118), on November 14, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.